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Cocaine dependence is a complex psychiatric disorder involving both genetic and environmental 
factors. Several neurotransmitter systems mediate cocaine’s effects, dependence and relapse, 
being the components of the neurotransmitter release machinery good candidates for the disorder. 
Previously, we identified a risk haplotype for cocaine dependence in the NSF gene, encoding the protein 
N-Ethylmaleimide-Sensitive Factor essential for synaptic vesicle turnover. Here we examined the 
possible contribution to cocaine dependence of a large copy number variant (CNV) that encompasses 
part of the NSF gene. We performed a case-control association study in a discovery sample (359 cases 
and 356 controls) and identified an association between cocaine dependence and the CNV (P = 0.013), 
that was confirmed in the replication sample (508 cases and 569 controls, P = 7.1e-03) and in a pooled 
analysis (P = 1.8e-04), with an over-representation of low number of copies in cases. Subsequently, 
we studied the functional impact of the CNV on gene expression and found that the levels of two NSF 
transcripts were significantly increased in peripheral blood mononuclear cells (PBMC) along with the 
number of copies of the CNV. These results, together with a previous study from our group, support the 
role of NSF in the susceptibility to cocaine dependence.
Cocaine dependence is a complex psychiatric disorder that results from the interaction between genetic and envi-
ronmental factors, with an estimated heritability of 65–79%1–3. Cocaine inhibits dopamine, serotonin and norep-
inephrine reuptake by binding to their transporters (DAT1, SERT and NET, respectively), increasing their levels 
at the synaptic cleft4,5. Also, other neurotransmitter pathways participate in cocaine dependence, withdrawal or 
relapse, including the glutamatergic, GABAergic and endocannabinoid systems6–12. Their involvement in medi-
ating cocaine effects and dependence makes the molecular machinery that controls neurotransmitter release to 
the synaptic cleft a strong candidate for participating in the development of cocaine dependence. As part of this 
complex process that involves many different proteins, the N-ethylmaleimide sensitive factor (NSF) plays an 
essential role in the synaptic vesicle turnover. NSF is responsible for the recycling of Soluble NSF Attachment 
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Protein Receptor (SNARE) complexes, preventing their accumulation and ensuring the maintenance of intracel-
lular membrane trafficking13.
Previous genetic evidence supports the contribution of single-nucleotide polymorphisms (SNPs) in the NSF 
gene to cocaine addiction, where a two-SNPs risk haplotype was associated with a rapid development of cocaine 
dependence, shortly after the first cocaine use14. To date, association studies with SNPs have unraveled only a 
small fraction of the estimated heritability for cocaine dependence. Thus, exploring structural variation may help 
to capture part of the missing heritability underlying this complex disorder15. Interestingly, a large copy number 
variant (CNV) of about 734 kb encompasses the first 13 exons of the NSF gene (including two additional genes, 
LRRC37A2 and ARL17A) and ranges from 2 to 6 copies per individual (1 to 3 haploid copies)16. In the European 
population, about 72% of individuals have more than two copies. This CNV is located immediately distal from the 
MAPT locus at 17q21.31, which was previously found to be subjected to positive selection and rapid evolutionary 
turnover, and associated with neurological disorders17.
Since CNVs are common forms of genetic variation that often impact gene expression and may have a greater 
effect on transcriptional regulation than that attributed to SNPs18–20, we hypothesize that the CNV spanning 
NSF has an influence on the expression of the gene and may contribute to cocaine dependence. To our knowl-
edge, association between CNVs and drug dependence has been explored mainly for alcohol or opioid depend-
ence21–24, but no study has investigated cocaine dependence so far. To address this issue, we explored the role of 
the CNV encompassing NSF in cocaine addiction through a two stage case-control association study with cocaine 
Figure 1. Delimitation of the CNV region. (a) Representation of the 3′ end of the CNV spanning the NSF 
gene. The CNV is indicated with a grey box, exons with black boxes, and triangles show the position of primers 
used in qRT-PCR assays. The location of SNP rs183211 is indicated. (b) Number of individuals grouped by 
copies of the NSF CNV in exons 2 and 13 and in intron 13.
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dependence. Subsequently, we studied the linkage disequilibrium (LD) between the previous associated SNPs and 
the CNV, as well as the impact of this CNV on NSF expression.
Results
A CNV encompassing part of the NSF gene was previously reported16. According to published data and informa-
tion in the Ensembl database (www.ensembl.org), it spans the first 13 exons of the gene. We refined the distal end 
of the CNV in our population by amplifying two NSF regions by quantitative real-time PCR (qRT-PCR), one in 
exon 13 and another one in intron 13 (Fig. 1a), and comparing the results with an internal CNV control in exon 2. 
All subjects were confirmed to bear only two copies of the DNA segment in intron 13, and a variable (and identi-
cal) number of copies in exons 13 and 2 (Fig. 1b), confirming that the CNV encompasses the first 13 exons of the 
gene in all 174 individuals assessed, ranging from 2 to 6 copies per diploid genome (Fig. 2).
In order to explore whether the NSF CNV was associated with cocaine dependence, we performed 
a case-control association study. The comparison of the number of copies of the CNV between 359 
cocaine-dependent patients and 356 controls showed significant differences between groups (P = 0.036, 
Supplementary Table S1). When we subdivided subjects into ‘low number of copies of the CNV’ (2 and 3) and 
‘high number of copies’ (4, 5 and 6), we identified a significant overrepresentation of low number of copies in 
Figure 2. Schematic representation of the CNV region. (a) Representation of genes NSF (ENSG00000073969),  
ARL17A (ENSG00000185829) and LRRC37A2 (ENSG00000238083). Exons are indicated with black boxes, 
CNV is indicated with a grey box. The location of the two SNPs previously associated with cocaine dependence 
is indicated. (b) Schema of genetic context of the three possible alleles of the CNV in this region: 1, 2 or 3 
repeats.
Genotype
Discovery Replication Pooled analysis1
Controls N (%) Cases N (%) Controls N (%) Cases N (%) Controls N (%) Cases N (%)
Low copy* 226 (63.5) 260 (72.4) 349 (61.3) 352 (69.3) 575 (62.2) 612 (70.6)
High copy** 130 (36.5) 99 (27.6) 220 (38.7) 156 (30.7) 350 (37.8) 255 (29.4)
SUM 356 359 569 508 925 867
p-value 0.01287 0.00713 0.00017
(OR −95% CI) 1.51 [1.10–2.07]& 1.42 [1.10–1.83]& 1.46 [1.19–1.78]&
Table 1.  Association study of the CNV in the NSF gene in cocaine-dependent Spanish patients. In bold: 
significant p-values. 1Discovery + replication samples. * Low copy genotype include genotypes 2 and 3. * * High 
copy genotype include genotypes 4, 5 and 6. &When OR < 1. the inverted score is shown.
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cocaine-dependent patients (72% vs 63%; P = 0.013; OR = 1.51, CI = [1.10–2.07]). This overrepresentation was 
replicated in an independent sample (69% vs 63%; P = 7.1e-03; OR = 1.42, CI = [1.10–1.83]). The pooled anal-
ysis of both the discovery and replication samples also rendered statistically significant results (71% vs 62%; 
P = 1.8e-04; OR = 1.459, CI = [1.20 –1.78]), which remained significant after adjusting by age (Padj = 3.1e-03), 
with a higher frequency of subjects carrying 2 or 3 copies of the NSF CNV in the group of cocaine-dependent 
subjects when compared to controls (Table 1).
Then, we observed that individuals with low number of copies showed an earlier dependence onset than indi-
viduals with high number of copies (P = 0.042). The main differences were observed in the group of patients that 
develop cocaine dependence within a year after the first drug use (Fig. 3). When we subdivided subjects in two 
subgroups, early (<1 year) and late (≥1 year) dependence onset, we identified an overrepresentation of individ-
uals with low number of copies in the group of patients showing early regular cocaine consumption (P = 5e-03; 
OR = 1.62, CI = [1.13–2.32]).
Previously, a SNP located in intron 13 of the NSF gene, rs183211, was associated with cocaine dependence 
either as a single marker or as part of a risk haplotype with rs17698176 (intron 17; Fig. 2a)14, also associated with 
an early onset of cocaine dependence. These two SNPs are located distal from the CNV according to our above 
experiments. Thus, we studied whether the associations between cocaine dependence and either the CNV or 
the two SNPs in the risk haplotype at NSF were related. To do so, we estimated SNP-CNV haplotype frequen-
cies using an expectation-maximization (EM) algorithm, and subsequently assessed LD between the CNV and 
rs183211 (Supplementary Table S2) and the CNV and the rs183211-rs17698176 risk haplotype (Table 2). We 
found that the rs183211G risk allele was associated with low number of copies at the CNV (P = 6e-12) as it was 
in moderate LD with one copy (r2 = 0.30). Furthermore, similar results were obtained for the risk haplotype: the 
rs183211G-rs17698176T haplotype allele was associated with low copy number of the CNV (P < 2.2e-16) as this 
previously reported risk haplotype was in LD with one copy (r2 = 0.61).
The two intronic SNPs previously reported to be associated with cocaine dependence, rs183211 and 
rs17698176, had no predicted functional effects according to the software SNP Function Prediction 
(snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). As we found association between the risk haploallele 
rs183211G-rs17698176T and low number of CNV copies, we subsequently explored the potential impact of 
the CNV on the expression of the NSF gene. Expression levels for NSF_001 (full length transcript), NSF_002 
(including the first four exons) and NSF_003 (including the last five exons) could be determined in PBMCs. 
Moreover, NSFP1, that spans the first 13 exons of the gene and seems to be a pseudogene that results from the 
CNV dynamics, encodes another transcript named NSFP1_001 (Fig. 2b). We analyzed the expression lev-
els of this last transcript with an assay that also detects one of the gene products, NSF_001 (Fig. 4a, primer 
pair ‘a’). As shown in Fig. 4b, the expression levels of transcripts NSF_001 + NSFP1_001 and NSF_002 
were significantly increased along with the number of copies of the CNV (P = 4.3e-06 and P = 8.9e-05, 
rs183211-rs17698176
CC GT AT
Copy number
1 0.0102 0.4984 0.0491
2 0.0632 0.0449 0.2312
3 0.0765 0.0046 0.0220
Table 2.  Haplotype frequencies in the NSF gene, including SNPs and CNV.
Figure 3. Time between initial consumption and onset of cocaine dependence (years) in individuals with 
low (2 or 3) and high (4, 5 or 6) number of copies of the NSF CNV. 
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respectively). Similar results were observed when the individuals were grouped into low and high number of cop-
ies, with transcript levels increased by 2.1-fold and 1.5-fold for NSF_001 + NSFP1_001 and NSF_002, respectively, 
in the group of high number of copies as compared to the group of low number of copies (P = 8.5e-09 and P = 3.7e-
04, respectively). Finally, we assessed the linearity of this correlation and found a significant association between 
the number of copies of the CNV and the level of transcripts NSF_001 + NSFP1_001 (ρ = 0.87, P = 9.4e-14) 
and NSF_002 (ρ = 0.68, P = 1.18e-06). As expected, no significant changes were observed for transcripts NSF_001 
and NSF_003, as they are encoded by genomic regions outside the CNV (Fig. 4b).
Discussion
Many studies have been performed to identify SNP variants associated with drug dependence and, even though 
some of them have reported significant findings, only a small fraction of the estimated heritability of this complex 
phenotype can be explained by them. Methodological limitations may account in part for the missing heritability, 
but other sources of genetic variation, like copy number variants, could also contribute to the genetic landscape 
of the disorder15. In this study, we identified a significant association between cocaine dependence and a CNV 
spanning the first 13 exons the NSF gene. To our knowledge, this is the first study that associates a CNV with 
cocaine dependence.
In a previous study, our group identified an association between a quick transition from cocaine use to 
dependence and a risk haplotype (rs183211G-rs17698176T) in the NSF gene. Furthermore, a large polymor-
phic CNV partially overlapping the NSF gene has been described16. We thus hypothesized that the NSF CNV 
could contribute to the susceptibility to cocaine dependence by altering gene expression. First, we performed a 
case-control association study and found a significant association between this CNV and cocaine dependence, 
Figure 4. Correlation between the number of copies of the CNV and gene expression. (a) Structure of 
transcripts detected by qRT-PCR assay. CNV is indicated with a grey box, exons are indicated with boxes in 
black for the NSF gene (ENSG00000073969) and in grey for NSF transcripts: NSF_001 (ENST00000398238), 
NSFP1_001 (ENST00000570034), NSF_002 (ENST00000486366) and NSF_003 (ENST00000465370). 
Arrows indicate the position of qRT-PCR primers sets used to detect the different transcripts: “a” for 
NSF_001 + NSFP_001, “b” for NSF_001, “c” for NSF_002 and “d” for NSF_003. (b) Blox plot for mRNA 
expression levels of each transcript in individuals with low and high number of copies. Linear regression 
showing the correlation between number of copies and transcript expression levels. Spearman’s rank correlation 
coefficients (ρ ) are shown inside the graphs. (**P < 0.001; ***P < 0.0001).
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with an overrepresentation of individuals with low number of copies in cocaine patients. Then, we observed that 
a low number of CNV copies correlated with a rapid development of dependence, and that the CNV and the pre-
viously described risk haplotype were in LD. Furthermore, we observed an effect of the CNV on NSF expression, 
identifying a positive correlation between the number of copies of the CNV and the levels of two transcripts, 
NSF_002 and NSFP1_001, both encoded by the segment of the gene that is included in the CNV. Since we had no 
access to brain samples, gene expression was assessed in samples obtained from PBMC, which may differ from 
brain NSF expression. Some studies, however, reveal a correlation in gene expression levels between peripheral 
blood and brain25.
In addition, we have characterized the 3′ end of the CNV, located within the NSF gene, and confirmed that 
the two disease-associated SNPs are located outside the CNV but in moderate LD with it. In consequence, the 
association identified previously, which was detected under the assumption of diploidy for the SNP variants, was 
calculated correctly and suggests that the two intronic SNPs may tag the NSF CNV.
CNVs play an important role in the generation of genetic diversity and so in human evolution. They have 
also been shown to have phenotypic effects, including susceptibility to disease, depending on whether or not 
dosage-sensitive genes or regulatory sequences are affected by the rearrangement26,27. Many genes involved in 
brain development are enriched in CNVs28, the biological importance as well as the evolutionary conservation 
of these genes suggest that they could have phenotype implications and might contribute to the susceptibility to 
complex neuropsychiatric disorders29,30. Genome-wide studies performed in drug abuse have unraveled a number 
of CNVs possibly contributing to drug dependence. For example, a CNV at 11q14.2 was found associated with 
variations in brain volume and drinking behaviour21, and losses at 22q13.1 seem to increase the response to alco-
hol in the precuneus, a region previously associated with severity of alcohol dependence (AD)22. Furthermore, a 
GWAS assessing common CNVs in AD in a Korean cohort identified losses at 20q13.33 as protective factors for 
AD23. Recently, a GWAS performed in opioid dependence (OD) identified many CNVs which could contribute 
to resistance or susceptibility to OD, three of them genome-wide significant24. These findings suggest that CNVs 
may have an important role in drug dependence. However, to our knowledge, the present study is the first one 
performed in cocaine dependence considering CNVs, and obtaining significant results.
The NSF gene encodes the hexameric ATPase N-ethylmaleimide-sensitive factor, which plays an essential 
role in the synaptic vesicle turnover, modulating the kinetics of neurotransmitters and the integrative proper-
ties of synapses31–33. NSF operates in the recycling of the SNARE complexes by preventing the accumulation of 
cis-complexes and assuring a sufficient amount of free SNARE for the maintenance of the intracellular membrane 
trafficking13. Furthermore, several studies suggest that NSF might modulate the function of several neurotrans-
mitters in the central nervous system by interacting with their receptors, such as the glutamatergic alpha-amino
-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPA), the beta-2 adrenergic receptor (β 2-AR), the 
dopamine receptors (more strongly D1 and D5), the adrenomedulin (AM) receptor, the γ -amino-butyric acid 
receptor (GABAA) and the serotonin transporter (SERT)34–46. Additionally, a recent study identified interactions 
between NSF and BLOC-1 (biogenesis of lysosome-related organelles complex 1), which participate in synaptic 
vesicle assembly, neurotransmission and plasticity, and this interaction modulates synaptic plasticity47.
Interestingly, a recent study showed that withdrawal from repeated cocaine exposure increased interactions 
between NSF and glutamate receptor 2 (GluR2), and this complex acts as a negative regulator of the expression of 
behavioral sensitization in rats48. Moreover, the NSF gene was found significantly down-regulated in postmortem 
hippocampus of cocaine addicts samples, which is consistent with our results showing an overrepresentation of 
low number of copies (which correlates with lower expression) in our sample of cocaine dependent patients49. 
Furthermore, NSF decrease correlates with a robust down-regulation of GABBR1 (Gamma-aminobutyric acid 
type B receptor subunit 1), a subunit of GABAB receptor, which could be used as a predictor for increased risk 
for addiction49. And in autistic patients, NSF expression was also found significantly reduced in lymphocytes and 
tended to be reduced in post-mortem brains, correlating with the severity of clinical traits46.
The CNV spanning the NSF gene was previously associated with elevated peak antibody response to the 
AVA-Biothrax vaccine, suggesting that this CNV has an effect on the expression of the genes in this region (NSF, 
ARL17 and LRRC37A)50. We have shown that a CNV spanning the NSF gene produces changes in the expression 
levels of some NSF transcripts, which could have an effect on the availability of neurotransmitter vesicles (loaded 
with e.g. dopamine, essential in the reward system) and its turnover, producing changes in the neurotransmitter 
release to the synaptic cleft. This would be in line with the “reward deficiency syndrome”, which hypothesizes 
that hypodopaminergic activity predisposes to cocaine dependence51. Although DA neurotransmission has been 
established as a central mediator in cocaine effects52–55, other neurotransmitters systems, such as the glutamater-
gic, GABAergic and endocannabinoid ones, also dependent on NSF activity, are very important and both associ-
ation studies and animal models support their role in cocaine dependence56–61.
The present case-control association study raises several methodological issues: (i) sample heterogeneity might 
alter the results of association studies. To minimize the risks we considered sex-matched Caucasian patients and 
controls from Spain, all of them recruited in a small geographical area around Barcelona and evaluated following 
a common clinical assessment; (ii) cocaine dependence was not discarded in the control sample. However, this 
problem, which tends to balance allele frequencies in cases and controls, would increase the probability of false 
negative results, which is not the case in the present study; (iii) qRT-PCR assays are widely used to validate CNVs 
because of its specificity and reproducibility, even though in some cases the results may fall between integers 
(e.g. copy number measuring 1.4), making interpretation difficult. Ambiguous results were discarded from our 
study in order to ensure a correct assignation of the number of copies in all cases; (iv) Hardy-Weinberg equilib-
rium (HWE) could not be tested in our samples since our genotyping strategy did not allow establishing phases. 
However, the effects of CNVs are usually related to genetic dose, therefore what matters is the total number of cop-
ies and not the phased genotype; (v) considering the number of CNV copies as low (2 and 3) or high (4, 5 and 6) 
is somehow arbitrary (Supplementary Table S1). In any case, if we consider individuals with 4 number of copies 
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into the ‘low’ group, the association remains statistically significant (P = 8.3e-04); (vi) we assessed the effect of the 
CNV on gene expression in RNA from PBMC, which may differ from expression in the brain; (vi) it is important 
to note that other genes in addition to NSF lie in the CNV and could also be contributing to cocaine dependence 
predisposition.
To conclude, we found a significant association between cocaine dependence and a CNV spanning the NSF 
gene. Functional studies revealed that the levels of two transcripts in blood, NSFP_001 and NSF_002, correlate 
with the number of copies of the CNV, suggesting that this CNV might have a functional impact on gene expres-
sion. These results, together with previous studies by our group14, suggest that NSF contributes to the genetic 
predisposition to cocaine dependence and, especially, to an early onset of dependence.
Materials and Methods
Delimitation of the copy number variation. The extension of the CNV spanning the NSF gene was 
ascertained in 174 individuals (89 controls and 85 cases). Detailed information about the subjects is provided in 
the ‘Association study’ section.
The number of copies at the CNV region and outside was assessed by qRT-PCR considering three regions of 
the NSF gene: exon 2, exon 13 and intron 13 (the latter located 102 bp 5′ from SNP rs183211, previously asso-
ciated with cocaine dependence) to narrow down the CNV extension. The albumin gene (ALB) was used as a 
diploid control. Primer sequences are available in Supplementary Table S3. QRT-PCR assays were performed as 
follows: 7.5 μ l of LightCycler® 480 SYBR Green I Master (Roche Life Sciences, Branford, CT, USA), 400 nM of 
each primer, 10 ng of DNA and PCR-grade water up to 15 μ l. The qRT-PCR conditions were: 10 min at 95 °C, 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. Specificity was ascertained after completion of the amplification in the 
presence of SYBR Green by the melting procedure (ramping from + 65 °C to + 97 °C, rising the temperature by 
2.2 °C at every step with 2-seconds intervals). QRT-PCR experiments were performed using the LightCycler® 480 
System and results were analyzed with the LightCycler® 480 Software, Version 1.5 (Roche Life Science, Branford, 
CT, USA). Standard curves for all amplicons were constructed through triplicate qRT-PCR amplifications with 
serial dilutions (factor of 2.5) of the DNA template and detection with SYBR Green. The final amount of template 
in the curve ranged from 300 ng to 3.14e-02 ng for DNA. Standard curves were used to determine the linearity 
(R2) and the efficiency (E)62 of the qRT-PCR amplifications and all transcripts were amplified with an efficiency 
around 94% (E = 1.94) and R2 = 0.9964, without significant differences among them. Five HapMap subjects with 
known number of copies at the NSF CNV (NA18506, NA19239, NA19240, NA12156, NA18942) were used as a 
reference for 2, 3, 4, 5 and 6 copies, respectively16. Genomic samples of these individuals were obtained from the 
Coriell Institute for Medical Research (New Jersey, USA) and were included in all assays as an internal control. 
NSF gene copy number was calculated by the comparative Ct (Δ Δ Ct) method and all experiments displaying 
ambiguous results were discarded from the study.
Association study. Subjects. The discovery sample consisted of 359 cocaine-dependent patients (mean 
age 35.5 ± 8.1 years, 81.3% males (n = 292)) and 356 controls (52.7 ± 16.8 years, 81.5% males (n = 290)). The rep-
lication sample consisted of 508 cocaine-dependent patients (mean age 35.7 ± 7.8 years, 79.9% males (n = 406)) 
and 569 controls (52.1 ± 16.9 years, 79.8% males (n = 454)). All patients were recruited and evaluated at the 
Psychiatry Department of the Hospital Universitari Vall d’Hebron (Barcelona, Spain) according to DSM-IV TR 
criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision) and the SCID (Structured 
Clinical Interview)63. A total of 75% of patients (n = 652) reported age at the initial consumption as well as age 
at dependence onset. All controls were recruited at the Blood and Tissues Bank of Barcelona. None of them had 
injected drugs intravenously. Patients and controls were Spanish, Caucasian and sex-matched. The study was 
approved by the ethics committee of our institution, the Institutional Review Board of the University of Barcelona 
(IRB00003099), and informed consent was obtained from all participants, in accordance with the Helsinki 
Declaration. Population stratification was previously discarded in our sample64.
DNA isolation and quantification. Genomic DNA was isolated from peripheral blood mononuclear cells 
(PBMC) using the salting-out method65. DNA concentrations were determined using NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Termo Fisher Scientific Inc., Wilmington, DE, USA).
Copy number assay. The number of copies of the CNV of each individual was assessed by qRT-PCR considering 
a region of exon 2 in the NSF gene. The albumin gene (ALB) was used as a diploid control. QRT-PCR conditions 
are described above. In all assays, samples with known number of copies at the NSF CNV were included, showing 
a concordance rate of 100%. All experiments displaying ambiguous results were not considered in the study.
Statistical analysis. The comparison of the number of copies of the CNV between cases and controls was per-
formed using the Fisher’s exact test (two-tailed), considering the five possible copy number assignations per indi-
vidual (from 2 to 6) and also a dichotomization into low (2 or 3 copies) and high (4, 5 or 6 copies) copy number. 
Age was considered as a covariate using binary logistic regression test. To analyze the effect of the number of cop-
ies of the CNV in the lapse between initial and regular consumption of cocaine, the comparison of medians was 
performed using the Mann-Whitney U non-parametric test as normality was rejected using Kolmgorov-Smirnov 
test. In addition, the time between initial consumption and onset of cocaine dependence was dichotomized intro 
early (< 1 years) or late (≥ 1 years) dependence onset, and the comparison of the number of copies of the NSF 
CNV between these groups was performed with the Fisher’s exact test (one-tailed). Statistical analysis was per-
formed using SPSS Statistics Version 22.0 software (IBM Corp. Released 2013. Armonk, NY).
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Linkage disequilibrium analysis. We estimated the allele and haplotype frequencies of the CNV and two 
NSF SNPs found previously associated with cocaine dependence (rs183211 and rs17698176)14. Genotypes for 
both SNPs and CNV were available for 47% of the sample used in the CNV association study (n = 407, 36.07 ± 9.5 
years, 85.7% males). Traditional approaches to assess LD between SNPs and CNVs are insufficient for higher 
order CNVs as the phase of the CNV cannot be directly inferred. To address this issue, we developed an EM 
algorithm-based method to estimate SNP-CNV haplotype frequencies under an assumption of Hardy-Weinberg 
equilibrium between haplotypes. The approach is similar to an existing method66. The algorithm begins by seed-
ing initial SNP-CNV haplotype frequencies according to known SNP-CNV genotype counts (e.g., an individual 
with a homozygote AA SNP genotype and 2 copies of the CNV would likely have two copies of a haplotype which 
included the A SNP allele and a single copy of the CNV). In the E-step, haplotype counts are calculated based on 
the estimated haplotype frequencies; followed by the M-step, which recalculates haplotype frequencies based on 
the estimated haplotype counts. This process is repeated in an iterative fashion until the haplotype frequencies 
become constant from one iteration to the next. In this study, the frequency estimates were constant to five dec-
imal places by the twentieth iteration. To estimate these haplotype frequencies, genotype data for rs183211 and 
rs17698176 from the 407 individuals previously described was used. From the resulting haplotype frequencies, 
we then assessed linkage disequilibrium (r2) between rs183211 and low number of copies of the CNV (individuals 
with 2 and 3 copies). Furthermore, we likewise assessed LD between the rs183211-rs17698176 haplotype and low 
number of copies of the CNV.
NSF expression assays. To correlate the number of copies of the CNV with NSF transcription levels, 45 
Spanish, Caucasian, healthy volunteers (mean age 32.8 ± 11.8 years, 66.7% females (n = 30)) were recruited 
at the Genetics Department of the University of Barcelona (Barcelona, Spain). Genomic DNA was isolated as 
previously described. Total RNA was extracted from PBMC within 2 h after sampling using BD Vacutainer® 
CPTTM tubes (BD, Franklin Lakes, NJ, USA) and the High Pure RNA Isolation Kit (Roche Life Science, Branford, 
CT, USA). RNA was retro-transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA). Specific primers were designed to detect each of the eight NSF 
transcripts according to ENSEMBL, as well as NSFP1, a pseudogene that probably arose as a consequence of the 
CNV dynamics. Three transcripts could be amplified specifically: NSF_001 (primers set ‘b’ in Fig. 4a), NSF_002 
(primers set ‘c’) and NSF_003 (primers set ‘d’) (ENST00000398238, ENST00000486366 and ENST00000465370, 
respectively, according to Ensembl release 83). For NSFP1_001 (ENST00000570034.1) we could not design spe-
cific primers since it overlaps with NSF_001; for this reason we designed a qRT-PCR assay to detect simultane-
ously both transcripts (primers set ‘a’). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase (HPRT1) were used to normalize the relative amounts of mRNA. QRT-PCR assays 
were performed as described above and all transcripts were amplified with an efficiency around 94% (E = 1.94) 
and R2 = 0.9963, without significant differences among them.
Statistical analysis. Expression levels of each transcript were compared among the five groups generated 
according to the number of copies of the CNV per individual (from 2 to 6) or between low and high CNV 
copies using Kruskal-Wallis and Mann-Whitney U non-parametric tests, respectively. In both cases normality 
was previously rejected using the Kolmogorov-Smirnov test. To estimate the relationship among the number of 
copies of the CNV and the expression levels of each transcript, a linear regression analysis was performed and 
its correlation was confirmed using the Spearman’s rank correlation coefficient (ρ ), threshold set at P < 0.05 
in all tests. Statistical analysis was performed using SPSS Statistics Version 22.0 software (IBM Corp. Released 
2013. Armonk, NY).
Ethics statement. This study was approved by the local Ethics Committee and informed consent was 
obtained from all adult subjects, children, and their parents according to the Helsinki declaration.
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